Medifast (MED) Stock Price, News & Analysis

Company Overview

Medifast, Inc. (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions. The company went public in 2001 and has since expanded its operations beyond the United States, serving customers in both the U.S. and Canada. Its offerings are distributed through a combination of e-commerce platforms and regional distribution centers, enabling efficient delivery of products to end users and reinforcing Medifast’s direct‐to‐consumer business model.

Under the leadership of President and Chief Executive Officer Daniel Chard, Medifast continues to invest in product innovation, digital tools and community building to strengthen customer engagement and retention. The company’s management team emphasizes evidence‐based program development and high standards of quality control, reflecting its commitment to clinical rigor and long‐term client success. With a focus on metabolic health and sustainable lifestyle transformation, Medifast aims to maintain its position as a leader in the weight‐management industry.

Key Stats

• Today's Range: $12.37 to $12.77
• 50-Day Range: $9.50 to $13.01
• 52-Week Range: $9.22 to $15.46
• Volume: 143,900 shs
• Average Volume: 199,627 shs
• Market Capitalization: $139.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Reduce

Medifast Stock Analysis - MarketRank™

Medifast scored higher than 41% of companies evaluated by MarketBeat, and ranked 115th out of 150 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Medifast has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Medifast is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Medifast has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Medifast are expected to grow in the coming year, from ($2.00) to ($1.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medifast is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medifast is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medifast has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.98% of the float of Medifast has been sold short.

Short Interest Ratio / Days to Cover

Medifast has a short interest ratio ("days to cover") of 13.19, which indicates bearish sentiment.

Change versus previous month

Short interest in Medifast has recently decreased by 6.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medifast does not currently pay a dividend.

Dividend Growth

Medifast does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.99

News Sentiment

Medifast has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Consumer Staples companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Medifast this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for MED on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Medifast in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $241,675.00 in company stock, which represents 0.1727% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Medifast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $241,675.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

3.70% of the stock of Medifast is held by insiders.

Percentage Held by Institutions

95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/15/2026
• Next Earnings (Estimated): 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Consumer Staples
• Industry: FOOD - MISC/DIVERSIFIED
• Sub-Industry: Personal Products
• Current Symbol: NYSE:MED
• CIK: 910329
• Web: www.medifast1.com
• Phone: (410) 581-8042
• Fax: 410-581-8070
• Employees: 870
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Medifast: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: -4.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.67 million
• Net Margins: -5.78%
• Pretax Margin: -2.34%
• Return on Equity: -4.80%
• Return on Assets: -3.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.80
• Quick Ratio: 4.30

Sales & Book Value

• Annual Sales: $385.79 million
• Price / Sales: 0.36
• Cash Flow: $0.42 per share
• Price / Cash Flow: 30.07
• Book Value: $17.78 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 11,120,000
• Free Float: 10,708,000
• Market Cap: $139.96 million
• Optionable: Optionable
• Beta: 0.55